Hospital News and Research

RSS

Vaccine and drug combination cuts melanoma recurrence by half

The combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence by 49 percent, a new study shows.

1 Jun 2026

Healthy lifestyles reduce cardiovascular risks for childhood cancer survivors

Healthy lifestyles can reduce the risk of cardiovascular disease and other complications in childhood cancer survivors.

1 Jun 2026

Post-discharge oral antibiotics show no benefit for pediatric appendicitis

Acute appendicitis is one of the most common surgical emergencies among children, and complicated acute appendicitis (CAA), including perforated or gangrenous disease, carries a higher risk of infection and longer hospitalization.

1 Jun 2026

Remote AI algorithm reliably detects safety criteria in pediatric surgery

Laparoscopic cholecystectomy is increasingly performed in children, yet bile duct injury remains a serious and potentially devastating complication.

1 Jun 2026

Health workers face hidden exposure to cancer-linked hazards

A study reveals high exposure to cancer risk factors among health and social care workers in Europe, underscoring the need for enhanced protective measures.

1 Jun 2026

Online resources on AI and cancer lack quality, need improvement

Online information about artificial intelligence (AI) and its impact on cancer research and treatment for both the patient and general-public audiences is limited, and the available webpages and videos are largely of low quality, difficult to read, and frequently omit risks of AI use, according to new research presented today at the at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9000) and led by researchers from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn's Perelman School of Medicine.

1 Jun 2026

New imaging method distinguishes inflammation from lung fibrosis

A new SPECT/CT imaging approach can accurately differentiate inflammation from fibrosis in interstitial lung disease (ILD) patients, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.

1 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026

Predictive model helps tailor PSMA therapy for prostate cancer patients

A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy begins.

31 May 2026

High-risk prostate cancer patients benefit from perioperative apalutamide therapy

High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

31 May 2026

Daraxonrasib significantly extends survival in metastatic pancreatic cancer

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

31 May 2026

Denzel Ward encourages lifesaving Hands-Only CPR action across Cleveland

Cleveland Browns cornerback and American Heart Association Nation of Lifesavers™ NFL Player Ambassador Denzel Ward is taking his impact beyond the field and into the heart of the city appearing on new billboards across Cleveland for National CPR and AED Week, June 1-7 annually.

29 May 2026

Gene test helps many breast cancer patients avoid chemotherapy

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found.

29 May 2026

Researchers develop open source framework for health AI research

A research team led by Columbia University has developed an open-source framework designed to streamline and accelerate artificial intelligence research using health data, addressing longstanding challenges in data standardization, reproducibility, and collaboration across institutions.

29 May 2026

Healthy lifestyles reduce chronic health risks for childhood cancer survivors

Healthy lifestyles can reduce the risk of cardiovascular disease and other complications in childhood cancer survivors. These are the findings of two new international studies.

29 May 2026

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.

29 May 2026